OBJECTIVES: Limited information is available on the impact of BRCA1/2 mutations on patient reported general health status (GHS). This study describes GHS differences based on BRCA1/2 mutation status in human epidermal growth factor receptor 2-negative (HER2-) US adult women with advanced breast cancer (ABC).

METHODS: Oncologists extracted data from patient charts of US adult women with HER2- ABC in a real world study via the Adelphi Advanced Breast Cancer Disease Specific Program. A subset of patients reported GHS via the EuroQol-5D-3L (EQ-5D-3L) and Visual Analogue Scale (VAS). Patients were categorized into 3 mutually exclusive cohorts; BRCA1/2 mutations (BRCAm), BRCA wild type (BRCAwt) and BRCA unknown (BRCAunk). Data were merged from 2015 and 2017 data collection. Differences in patient demographics were compared between BRCAm vs BRCAwt using t-tests and Pearson’s Chi-squared tests. GHS scores are presented descriptively.

RESULTS: Overall 279 patients completed >1 GHS questionnaires; BRCAm n=18, BRCAwt n=116, BRCAunk n=145. The mean age across all cohorts was 64.1 years; patients with BRCAm were significantly younger than BRCAwt (54.5 vs. 61.9), [P=0.011]. Additionally, patients with BRCAm were more likely to have a family history of breast or ovarian cancer than BRCAwt (55.6% vs. 14.7%), [P=0.003]. Numerically lower GHS scores were reported in patients with BRCAm (mean EQ-5D overall index score=0.7 [SD: 0.2], mean VAS score=53.6 [SD: 18.1]) relative to BRCAwt (mean EQ-5D overall index score=0.8 [SD: 0.2], mean VAS score= 58.7 [SD: 22.4]) and BRCAunk (mean EQ-5D overall index score=0.8 [SD: 0.2], mean VAS score=67.7 [SD: 20.5]) patients.

CONCLUSIONS: In this study, adult females with HER2- ABC, patients with BRCAm vs. BRCAwt were significantly younger and more likely to have a family history of breast or ovarian cancer. Numerically worse GHS scores were observed in patients with BRCAm relative to BRCAwt/BRCAunk. Future larger studies are warranted to validate these conclusions.